The Malignant Fibrous Histiocytoma drugs in development market research report provides comprehensive information on the therapeutics under development for Malignant Fibrous Histiocytoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Malignant Fibrous Histiocytoma. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Malignant Fibrous Histiocytoma and features dormant and discontinued products.
GlobalData tracks 19 drugs in development for Malignant Fibrous Histiocytoma by 17 companies/universities/institutes. The top development phase for Malignant Fibrous Histiocytoma is phase ii with eight drugs in that stage. The Malignant Fibrous Histiocytoma pipeline has 19 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Malignant Fibrous Histiocytoma pipeline products market are: Bristol-Myers Squibb, Hutchison MediPharma and Avacta Life Sciences.
The key targets in the Malignant Fibrous Histiocytoma pipeline products market include Macrophage Colony Stimulating Factor 1 Receptor, Programmed Cell Death Protein 1, and Vascular Endothelial Growth Factor Receptor.
The key mechanisms of action in the Malignant Fibrous Histiocytoma pipeline product include Macrophage Colony Stimulating Factor 1 Receptor Inhibitor with seven drugs in Pre-Registration. The Malignant Fibrous Histiocytoma pipeline products include eight routes of administration with the top ROA being Intravenous and four key molecule types in the Malignant Fibrous Histiocytoma pipeline products market including Small Molecule, and Monoclonal Antibody.
Malignant Fibrous Histiocytoma overview
Malignant fibrous histiocytoma, now termed undifferentiated pleomorphic sarcoma (UPS), is thought to originate from primitive mesenchymal cells, emerging in soft tissue or bone, typically in the extremities or retroperitoneum. Most common in late adulthood, it exhibits a slight male predominance, constituting the most prevalent soft tissue sarcoma. The subtypes include storiform/pleomorphic, myxoid, giant cell, inflammatory, and angiomatoid. Diagnostic imaging, such as computed tomography (CT) or magnetic resonance imaging (MRI), aids in defining disease extent. Predominantly, the treatment approach involves surgical intervention due to the absence of a singular cure for this neoplasm categorized within the undifferentiated/unclassified sarcomas group.
For a complete picture of Malignant Fibrous Histiocytoma’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
